Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

280
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
Hepatic Portal System01:21

Hepatic Portal System

5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

244
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
244
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

581
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
581
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

309
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
309
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanism of Alzheimer type II astrocyte development in hepatic encephalopathy.

Neurochemistry international·2024
Same author

Age and Sex in the Development of Hepatic Encephalopathy: Role of Alcohol.

Biology·2024
Same author

Multi-Organ Histopathological Changes in a Mouse Hepatitis Virus Model of COVID-19.

Viruses·2021
Same author

Age as a determinant of inflammatory response and survival of glia and axons after human traumatic spinal cord injury.

Experimental neurology·2020
Same author

Additive Effect of Resveratrol on Astrocyte Swelling Post-exposure to Ammonia, Ischemia and Trauma In Vitro.

Neurochemical research·2020
Same author

Aberrant Brain Bile Acid Signaling and Cholesterol Accumulation: A New Look at Mechanisms in Hepatic Encephalopathy.

Cellular and molecular gastroenterology and hepatology·2018
Same journal

Corrigendum to "Nuances in ATP7B Genetic Testing and Interpretation in India" [J Clin Exp Hepatol 16 (1) (2026) 103205].

Journal of clinical and experimental hepatology·2026
Same journal

Hepatic Melioidosis: A State-of-the-Art Review.

Journal of clinical and experimental hepatology·2026
Same journal

Overlap Syndromes and Associated Immunoglobulin-G4-Related Liver Diseases.

Journal of clinical and experimental hepatology·2026
Same journal

Redefinition of Fatty Liver Disease: Stigma or Fatphobia?

Journal of clinical and experimental hepatology·2026
Same journal

Relative Adrenal Insufficiency in Decompensated Cirrhosis With Hyponatremia: Disease Severity Marker or Therapeutic Target?

Journal of clinical and experimental hepatology·2026
Same journal

Liver Transplant Outcomes in Patients With Transjugular Intrahepatic Portosystemic Shunt: A Retrospective Cohort Study With Propensity Score Analysis.

Journal of clinical and experimental hepatology·2026
See all related articles

Related Experiment Video

Updated: Feb 4, 2026

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
08:47

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia

Published on: November 19, 2008

36.4K

Hyperammonemia in Hepatic Encephalopathy.

A R Jayakumar1,2, Michael D Norenberg3,4,5

  • 1General Medical Research, Neuropathology Section, R&D Service, Veterans Affairs Medical Center, Miami, FL 33125, United States.

Journal of Clinical and Experimental Hepatology
|October 11, 2018
PubMed
Summary
This summary is machine-generated.

Hepatic Encephalopathy (HE) neurotoxicity is complex, but ammonia plays a vital role. This review examines ammonia

Keywords:
AHE, Acute Hepatic EncephalopathyALF, Acute Liver FailureCHE, Chronic Hepatic EncephalopathyCNS, Central Nervous SystemCSF, Cerebrospinal FluidECs, Endothelial CellsHE, Hepatic EncephalopathyIL, InterleukinLPS, LipopolysaccharideMAPKs, Mitogen-Activated Protein KinasesNCX, Sodium-Calcium ExchangerNF-κB, Nuclear Factor-kappaBNHE, Sodium/Hydrogen Exchanger-1 or SLC9A1 (SoLute Carrier Family 9A1)SUR1, The Sulfonylurea Receptor 1TDP-43 and tau proteinopathiesTDP-43, TAR DNA-Binding Protein, 43 kDaTLR, Toll-like ReceptorTNF-α, Tumor Necrosis Factor-AlphaTSP-1, Thrombospondin-1ammoniahepatic encephalopathyinflammationmatricellular proteins

More Related Videos

A Novel Method to Model Chronic Traumatic Encephalopathy in Drosophila
10:15

A Novel Method to Model Chronic Traumatic Encephalopathy in Drosophila

Published on: July 4, 2017

8.7K
A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

20.2K

Related Experiment Videos

Last Updated: Feb 4, 2026

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
08:47

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia

Published on: November 19, 2008

36.4K
A Novel Method to Model Chronic Traumatic Encephalopathy in Drosophila
10:15

A Novel Method to Model Chronic Traumatic Encephalopathy in Drosophila

Published on: July 4, 2017

8.7K
A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

20.2K

Area of Science:

  • Neuroscience
  • Hepatology
  • Toxicology

Background:

  • Hepatic Encephalopathy (HE) neurotoxicity mechanisms remain unclear.
  • Gut-derived toxins, particularly ammonia, are implicated in HE pathogenesis.
  • Recent studies suggest other factors like cytokines may also contribute.

Purpose of the Study:

  • To review the role of ammonia in HE pathogenesis.
  • To highlight molecular mechanisms of neurological complications in liver failure.
  • To discuss recent advances and ongoing debates in HE research.

Main Methods:

  • Literature review of human and animal studies on HE and ammonia.
  • Analysis of clinical, pathological, and biochemical data.
  • Examination of experimental models of acute and chronic liver failure.

Main Results:

  • Elevated ammonia levels worsen HE; reduction alleviates symptoms.
  • Ammonia exposure in animals and cell cultures reproduces HE findings.
  • Evidence supports ammonia's critical role, though other factors are also considered.

Conclusions:

  • Ammonia is a key factor in HE neurotoxicity, supported by extensive evidence.
  • Molecular mechanisms of HE progression are increasingly understood.
  • Further research is needed to fully elucidate HE pathogenesis and develop targeted therapies.